See more : Mentice AB (publ) (MNTC.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Capricor Therapeutics, Inc. (CAPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capricor Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Angold Resources Ltd. (AAUGF) Income Statement Analysis – Financial Results
- Birchcliff Energy Ltd. (BIR.TO) Income Statement Analysis – Financial Results
- Clearmind Medicine Inc. (CMND.CN) Income Statement Analysis – Financial Results
- Kenmare Resources plc (KMRPF) Income Statement Analysis – Financial Results
- SPT Energy Group Inc. (1251.HK) Income Statement Analysis – Financial Results
Capricor Therapeutics, Inc. (CAPR)
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.18M | 2.55M | 244.90K | 310.25K | 1.01M | 1.67M | 1.37M | 3.19M | 3.78M | 4.79M | 503.23K | 195.50K | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 694.87K | 245.70K | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.11M | 1.85M | -799.00 | -8.15M | -4.14M | -10.40M | -9.40M | -12.85M | -9.98M | -3.00M | -4.69M | -2.44M | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 95.75% | 72.74% | -0.33% | -2,625.87% | -411.61% | -621.98% | -687.46% | -402.87% | -264.33% | -62.69% | -932.76% | -1,247.43% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 36.45M | 21.82M | 13.57M | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 1.02M | 4.14M | 4.08M | 4.47M | 9.48M | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43K | 0.00 |
| SG&A | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.22K | 10.43K | 0.00 |
| Other Expenses | 0.00 | 190.58K | 548.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 545.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00 | 26.09K | 200.00 |
| Operating Expenses | 48.19M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Cost & Expenses | 49.26M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Interest Income | 1.73M | 0.00 | 57.46K | 32.94K | 94.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23K | 6.01K | 20.38K | 47.19K | 332.72K | 287.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 398.81K | 344.67K | 248.63K | 200.51K | 58.13K | 0.00 | 0.00 | 0.00 | 0.00 | 137.00 | 1.09M | 950.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.07M | 694.87K | 245.70K | 143.89K | 171.96K | 157.65K | 144.17K | 134.64K | 110.87K | 41.90K | 26.92K | 6.26K | 7.51K | 12.93K | 159.59K | 113.29K | 26.98K | 0.00 | 0.00 | -900.00 | 0.00 | -2.19K | 83.00 | 200.00 | 200.00 |
| EBITDA | -23.01M | -29.16M | -20.69M | -13.55M | -7.56M | -15.17M | -12.72M | -18.33M | -12.50M | -5.97M | -6.88M | -1.89M | -4.88M | -6.02M | -7.71M | -13.02M | -9.50M | -2.50M | -18.86K | -19.88K | -16.16K | -19.97K | -22.22K | -36.32K | 200.00 |
| EBITDA Ratio | -91.39% | -1,184.21% | -8,700.01% | -4,423.18% | -778.68% | -917.04% | -940.79% | -532.16% | -334.00% | -124.85% | -1,366.36% | -1,244.33% | -361.76% | 0.00% | 0.00% | 0.00% | -9,342.68% | 0.00% | 0.00% | 0.00% | -739.79% | -173.90% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.08M | -29.70M | -20.94M | -13.69M | -7.73M | -15.33M | -12.86M | -16.98M | -12.61M | -6.02M | -6.90M | -2.44M | -4.90M | -6.29M | -7.88M | -13.40M | -9.50M | -60.40K | -18.86K | -18.98K | -16.16K | -17.78K | -22.30K | -36.52K | -200.00 |
| Operating Income Ratio | -95.63% | -1,165.10% | -8,549.86% | -4,412.56% | -769.52% | -917.04% | -940.79% | -532.16% | -334.00% | -125.72% | -1,371.71% | -1,248.15% | -361.70% | 0.00% | 0.00% | 0.00% | -9,369.29% | 0.00% | 0.00% | 0.00% | -739.79% | -154.82% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.79M | 677.85K | 915.92K | 32.94K | 92.07K | 135.99K | 15.29M | -1.83M | -245.51K | -198.61K | -1.99M | 207.00K | 14.39K | 262.06K | 11.41K | 268.39K | -802.34K | -950.00 | 0.00 | 900.00 | 16.16K | 2.19K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -22.29M | -29.02M | -20.02M | -13.66M | -7.64M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88B | -6.03B | -7.87B | -13.13B | -10.30M | -61.35K | 0.00 | -18.08K | 0.00 | -15.59K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -88.52% | -1,138.50% | -8,175.86% | -4,401.94% | -760.36% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360,633.89% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | 0.00% | -135.73% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -677.85 | -613.41K | -176.83K | -264.03K | 135.99K | 254.63K | 218.95K | 137.76K | 200.51K | 58.13K | 0.00 | -14.39K | -262.06K | -11.41K | -268.39K | 1.09M | 0.00 | 18.86K | 0.00 | 16.16K | 0.00 | 0.00 | 0.00 | 200.00 |
| Net Income | -22.29M | -29.02M | -19.41M | -13.48M | -7.38M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88M | -6.03M | -7.87M | -13.13M | -10.30M | -61.35K | -18.86K | -18.08K | -16.16K | -15.59K | -22.30K | -36.52K | -200.00 |
| Net Income Ratio | -88.52% | -1,138.48% | -7,925.38% | -4,344.95% | -734.09% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360.63% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | -739.79% | -135.73% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| EPS Diluted | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 0.90 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| Weighted Avg Shares Out | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.32M | 1.86M | 1.59M | 1.17M | 1.05M | 994.52K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
| Weighted Avg Shares Out (Dil) | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.68M | 1.86M | 1.59M | 1.17M | 1.05M | 994.53K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Good...
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with...
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial...
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002's Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-
Capricor Therapeutics Announces $23 Million Registered Direct Offering
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it...
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002's Path Towards a Biologics License Application (BLA)-
Source: https://incomestatements.info
Category: Stock Reports